These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

727 related items for PubMed ID: 17237840

  • 21. Bone disease in uremic patients: advances in PTH suppression.
    Brancaccio D, Cozzolino M, Gorio A, Di Giulio AM, Gallieni M.
    J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
    [Abstract] [Full Text] [Related]

  • 22. Parathyroid growth and suppression in renal failure.
    Lewin E, Huan J, Olgaard K.
    Semin Dial; 2006; 19(3):238-45. PubMed ID: 16689976
    [Abstract] [Full Text] [Related]

  • 23. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [Abstract] [Full Text] [Related]

  • 24. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
    Pulvirenti D, Aikaterini T, Campagna A, Ignaccolo L, Giustolisi N, Costa E.
    Clin Ter; 2008 Jun; 159(5):307-10. PubMed ID: 18998031
    [Abstract] [Full Text] [Related]

  • 25. [Ratio of serum levels of 1,25-dihydroxyvitamin D3 and parathyroid hormone for the diagnosis and treatment of tuberculous peritonitis in a chronic kidney disease patient: a case report].
    Oka H, Miishima N, Yoshitomi R, Mizobuchi T, Kamimura T, Sugawara K, Harada A.
    Nihon Jinzo Gakkai Shi; 2010 Jun; 52(5):584-9. PubMed ID: 20715591
    [Abstract] [Full Text] [Related]

  • 26. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D.
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [Abstract] [Full Text] [Related]

  • 27. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
    Goodman WG.
    Semin Dial; 2004 Jul; 17(3):209-16. PubMed ID: 15144547
    [Abstract] [Full Text] [Related]

  • 28. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS, Karagiannis PC, Peyerl FW.
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [Abstract] [Full Text] [Related]

  • 29. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Gene therapy for secondary hyperparathyroidism].
    Kanai G, Fukagawa M.
    Clin Calcium; 2010 Jul; 20(7):1052-9. PubMed ID: 20585184
    [Abstract] [Full Text] [Related]

  • 30. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M.
    J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
    [Abstract] [Full Text] [Related]

  • 31. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
    Rodriguez M, Nemeth E, Martin D.
    Am J Physiol Renal Physiol; 2005 Feb; 288(2):F253-64. PubMed ID: 15507543
    [Abstract] [Full Text] [Related]

  • 32. Statins do not affect mineral metabolism in chronic kidney disease: a retrospective analysis.
    Ashman N, Banerjee A, Yaqoob MM.
    Nephron Clin Pract; 2009 Feb; 111(4):c236-9. PubMed ID: 19287183
    [Abstract] [Full Text] [Related]

  • 33. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.
    Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M.
    Am J Kidney Dis; 2009 Mar; 53(3):408-16. PubMed ID: 19185400
    [Abstract] [Full Text] [Related]

  • 34. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D.
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [Abstract] [Full Text] [Related]

  • 35. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
    Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M.
    Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
    [Abstract] [Full Text] [Related]

  • 36. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D, Tatematsu M.
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [Abstract] [Full Text] [Related]

  • 37. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 38. [Treatment of secondary hyperparathyroidism in dialysis patients].
    Di Luca M.
    G Ital Nefrol; 2009 Jun; 26 Suppl 49():S36-48. PubMed ID: 19941277
    [Abstract] [Full Text] [Related]

  • 39. Vitamin D analogs: perspectives for treatment.
    Brown AJ, Slatopolsky E.
    Miner Electrolyte Metab; 1999 Jun; 25(4-6):337-41. PubMed ID: 10681662
    [Abstract] [Full Text] [Related]

  • 40. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.
    J Nephrol; 2009 Jun; 22(1):59-68. PubMed ID: 19229819
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.